BRIDGEWATER, N.J. - Insmed (NASDAQ:INSM) Incorporated (NASDAQ:INSM), a global biopharmaceutical company, today shared new data at the American Thoracic Society 2024 International Conference, indicating that ARIKAYCE (amikacin liposome inhalation suspension) combined with a macrolide-based regimen could be more effective in treating nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC) than the regimen alone.
The ARISE study showed that ARIKAYCE-treated patients experienced greater improvements in respiratory symptoms as measured by the Quality of Life-Bronchiectasis (QOL-B) respiratory domain instrument.
Notably, 43.8% of ARIKAYCE patients saw a meaningful improvement in QOL-B respiratory scores, compared to 33.3% in the comparator arm. Furthermore, ARIKAYCE patients continued to improve through Month 7, including one month off treatment, while improvements in the comparator arm plateaued after Month 3 and declined after Month 6.
Microbiologic data also revealed that ARIKAYCE patients had numerically greater rates of culture conversion by Month 6 and nominally statistically significantly higher rates by Month 7, with an earlier time to first culture conversion compared to the comparator arm. Importantly, no study patients developed MAC resistance to ARIKAYCE or macrolides.
The ARISE trial was not designed to show a statistically significant difference between treatment arms, but a strong trend toward significance was observed. The study's discontinuation rate was higher in the ARIKAYCE arm (22.9%) compared to the comparator arm (7.8%), but no new safety signals were observed, and the most common treatment-emergent adverse events were consistent with known side effects.
These findings are significant for patients with NTM lung disease, a challenging condition with limited treatment options. Insmed's Chief Medical Officer, Dr. Martina Flammer, emphasized the importance of these results for the NTM community and the potential for ARIKAYCE to serve a broader population with MAC lung disease.
The company also presented seven additional abstracts at the conference, contributing to the understanding of serious pulmonary diseases and showcasing data on their investigational medicine brensocatib.
Insmed's ARIKAYCE, the first FDA-approved therapy for MAC lung disease in patients with limited treatment options, is currently under a Phase 3b registrational study (ENCORE) to support a supplemental new drug application for broader use.
These results are based on a press release statement and have not been independently verified. The safety and efficacy of ARIKAYCE will continue to be evaluated in ongoing clinical trials.
InvestingPro Insights
As Insmed Incorporated (NASDAQ:INSM) showcases the potential benefits of ARIKAYCE for treating NTM lung infections, it's essential for investors to consider the company's financial health and market performance. According to InvestingPro data, Insmed has a market capitalization of $3.8 billion. Despite a substantial gross profit margin of 78.07% over the last twelve months as of Q1 2024, the company's operating income margin was deeply negative at -215.75%, reflecting significant operating losses.
InvestingPro Tips highlight some concerns, as analysts have recently lowered their earnings expectations for the upcoming period, and the consensus is that the company will not be profitable this year. Moreover, Insmed has been operating at a loss over the last twelve months and does not pay a dividend, which may influence the investment decisions of income-focused shareholders.
Still, it is worth noting that the company has experienced a 22.54% revenue growth over the last twelve months, indicating an expanding business scale that could eventually lead to profitability. For investors interested in more in-depth analysis, there are additional InvestingPro Tips available at https://www.investing.com/pro/INSM. Using the coupon code PRONEWS24, readers can get an extra 10% off a yearly or biyearly Pro and Pro+ subscription to access these valuable insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.